Bo-Feng Luo

Dendritic-cell-targeting adeno-associated virus as potent cancer vaccine carriers

The clinical efficacy of therapeutic cancer vaccines is critically limited by the inefficient in vivo delivery of tumor antigens to dendritic cells (DCs), the key regulators of T-cell immunity. To address this issue, we developed a dendritic-cell-targeting adeno-associated virus (AAV) vector through ra...